Skip to main content
SpringerLink
Log in

Is maternal aP immunisation good value for money in LMICs?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The vaccine is currently under development.

Reference

  • Russell LB, et al. What Pertussis Mortality Rates Make Maternal Acellular Pertussis Immunization Cost-Effective in Low- and Middle-Income Countries? A Decision Analysis. Clinical Infectious Diseases 63: S227-S235, Dec 2016. Available from: URL: http://doi.org/10.1093/cid/ciw558

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Is maternal aP immunisation good value for money in LMICs?. PharmacoEcon Outcomes News 767, 16 (2016). https://doi.org/10.1007/s40274-016-3576-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3576-1

Search

Navigation